SNGX
HEALTHCARESoligenix Inc
$0.33+0.01 (+4.06%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving SNGX Today?
No stock-specific AI insight has been generated for SNGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.30$6.23
$0.33
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-2.14
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume877K
Avg Volume (10D)—
Shares Outstanding10.3M
SNGX News
21 articles- Soligenix Announces Recent Updates and First Quarter 2026 Financial ResultsYahoo Finance·May 8, 2026
- SNGX: FLASH2 Trial Recommended to Stop for FutilityYahoo Finance·Apr 29, 2026
- SNGX Phase 3 Trial Halted on HyBryteAdvfn·Apr 28, 2026
- Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell LymphomaYahoo Finance·Apr 28, 2026
- Soligenix (SNGX) Highlights Patient-Centric Drug Development Strategy Through Reformulation ApproachYahoo Finance·Apr 21, 2026
- Soligenix (SNGX) Strengthens Pipeline as European Commission Grants SGX945 Orphan StatusYahoo Finance·Apr 20, 2026
- Soligenix (SNGX) Advances CTCL Research With Interim Analysis, Comparative Study ResultsYahoo Finance·Apr 17, 2026
- The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsightGlobeNewswire Inc.·Apr 14, 2026
- BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Apr 10, 2026
- SNGX: Interim Analysis for Phase 3 CTCL Study in 2Q26Yahoo Finance·Apr 6, 2026
- Soligenix (SNGX) Publishes Positive HyBryte Study Results In Oncology and TherapyYahoo Finance·Apr 2, 2026
- Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and TherapyBenzinga·Apr 2, 2026
- Soligenix (SNGX) Highlights Phase 3 CTCL Progress and Orphan Drug Milestones in 2025 ResultsYahoo Finance·Apr 1, 2026
- Soligenix Announces Recent Accomplishments and Year End 2025 Financial ResultsBenzinga·Mar 31, 2026
- Soligenix (SNGX) Receives EU Orphan Drug Designation For Dusquetide In Behcet DiseaseYahoo Finance·Mar 26, 2026
- Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's DiseaseBenzinga·Mar 26, 2026
- Soligenix (SNGX) Spotlighted in Recent Zacks Research Report as Key Clinical Milestones ApproachYahoo Finance·Mar 25, 2026
- Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD MeetingYahoo Finance·Mar 24, 2026
- Soligenix (SNGX) Strengthens Rare Disease Pipeline Program Through UK Regulatory Innovation DesignationYahoo Finance·Mar 23, 2026
- HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026Yahoo Finance·Mar 23, 2026
- Soligenix (SNGX) Highlights HyBryte Clinical Data in Peer-Reviewed Journal PublicationYahoo Finance·Mar 19, 2026
All 21 articles loaded
Price Data
Open$0.35
Previous Close$0.32
Day High$0.36
Day Low$0.34
52 Week High$6.23
52 Week Low$0.30
52-Week Range
$0.30$6.23
$0.33
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-2.14
Dividend Yield—
Dividend / Share—
ROE-2.4%
Profit Margin—
Debt / Equity—
Trading
Volume877K
Avg Volume (10D)—
Shares Outstanding10.3M
About Soligenix Inc
Soligenix, Inc., an advanced stage biopharmaceutical company, focuses on developing and marketing products to treat rare diseases in the United States. The company is headquartered in Princeton, New Jersey.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—